# Mitochondrial Neurological Disease

## Introduction

Mitochondrial diseases are a clinically and genetically heterogeneous group of disorders caused by dysfunction of the mitochondrial respiratory chain. Because the nervous system has high energy demands, neurological manifestations are frequently the presenting and most disabling features of mitochondrial disease. The dual genetic control of mitochondrial function (mitochondrial DNA and nuclear DNA) creates complex inheritance patterns and diagnostic challenges.

## Mitochondrial Genetics

### Mitochondrial DNA (mtDNA)

The mitochondrial genome is a circular, 16,569 base pair molecule encoding 13 respiratory chain subunits, 22 tRNAs, and 2 rRNAs. It is exclusively maternally inherited: affected mothers transmit mtDNA to all children, but only daughters can pass it to the next generation. Each cell contains hundreds to thousands of mtDNA copies (polyplasmy), and mutant and wild-type mtDNA can coexist within a single cell (heteroplasmy). The proportion of mutant mtDNA determines phenotypic severity through the threshold effect, whereby clinical manifestations appear when the mutant load exceeds a tissue-specific threshold, typically 60-90%. Mitotic segregation, the random distribution of mitochondria during cell division, can shift heteroplasmy levels, contributing to variable expressivity between tissues and between family members.

### Nuclear DNA (nDNA)

More than 1,500 nuclear genes encode mitochondrial proteins. Mutations in these genes follow Mendelian inheritance patterns (autosomal dominant, autosomal recessive, or X-linked) and are responsible for the majority of pediatric mitochondrial disease and many adult-onset cases. These mutations affect respiratory chain assembly, mtDNA maintenance (through genes such as POLG, TWNK, and RRM2B), mitochondrial dynamics, and cofactor biosynthesis.

## Clinical Manifestations

### Key Principle: Multisystem Involvement

Mitochondrial diseases preferentially affect tissues with the highest energy demands: brain, skeletal muscle, heart, eye, liver, and endocrine organs. The presence of unexplained multisystem disease should always raise suspicion for a mitochondrial etiology, and neurological features dominate in most presentations.

### Common Neurological Features

Encephalopathy presents as recurrent metabolic crises, often triggered by illness, fasting, or physiological stress. Seizures may be focal, generalized, or myoclonic and are often drug-resistant. Stroke-like episodes, the hallmark of MELAS, are not confined to vascular territories. Myopathy manifests as progressive external ophthalmoplegia, proximal weakness, and exercise intolerance. Cerebellar degeneration producing ataxia is prominent in many mitochondrial syndromes. Peripheral neuropathy may be axonal or mixed axonal-demyelinating. Sensorineural hearing loss is one of the most common features across mitochondrial disorders. Optic atrophy is prominent in Leber hereditary optic neuropathy and other mitochondrial conditions. Cognitive decline and developmental delay characterize pediatric presentations.

### Extra-Neurological Features (Clues to Diagnosis)

Features outside the nervous system provide important diagnostic clues, including short stature, diabetes mellitus, cardiomyopathy, cardiac conduction defects, renal tubular dysfunction, hepatopathy, pigmentary retinopathy, ptosis, ophthalmoplegia, and lactic acidosis with elevated serum and CSF lactate.

![Diagram showing the multisystem involvement of mitochondrial disease with organ-specific manifestations](images/mitochondrial-multisystem.jpg)

## Major Mitochondrial Syndromes

| Syndrome | Mutation | Key Features | Onset | Unique Clue |
|---|---|---|---|---|
| MELAS | m.3243A>G (MT-TL1) | Stroke-like episodes, seizures, dementia, lactic acidosis | Childhood/young adult | MRI lesions NOT in vascular territories |
| MERRF | m.8344A>G (MT-TK) | Myoclonus, epilepsy, ataxia, myopathy | Variable | Ragged red fibers on muscle biopsy |
| Kearns-Sayre | Large mtDNA deletion | PEO, pigmentary retinopathy, cardiac block | <20 years | Cardiac conduction block (pacemaker may save life) |
| LHON | m.11778G>A (most common) | Bilateral sequential painless visual loss | Young adult males | Peripapillary telangiectasia; idebenone treatment |
| NARP | m.8993T>G (MT-ATP6) | Neuropathy, ataxia, retinitis pigmentosa | Variable | Leigh syndrome at >90% heteroplasmy |
| CPEO | Various mtDNA/nuclear | Progressive external ophthalmoplegia, ptosis | Variable | Ragged red fibers; consider KSS features |

### MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes)

The most common causative mutation is m.3243A>G in MT-TL1 (tRNA-Leu). Onset is typically in childhood or young adulthood. Stroke-like episodes produce acute neurological deficits such as hemiparesis, hemianopia, and aphasia, with MRI lesions that characteristically do not respect vascular territories and preferentially affect the parietal and occipital lobes. Recurrent vomiting, headache, and seizures accompany episodes. Progressive dementia, hearing loss, short stature, and diabetes develop over time, and lactic acidosis is present in both serum and CSF. Treatment is supportive, with L-arginine given intravenously during acute episodes for vasodilation. Valproic acid must be avoided because it inhibits mitochondrial function. Taurine supplementation is under investigation.

### MERRF (Myoclonic Epilepsy with Ragged Red Fibers)

The most common mutation is m.8344A>G in MT-TK (tRNA-Lys). The syndrome features myoclonus, generalized epilepsy, ataxia, and myopathy. Muscle biopsy with modified Gomori trichrome stain reveals the characteristic "ragged red fibers" representing subsarcolemmal accumulation of abnormal mitochondria. Lipomas, hearing loss, and neuropathy are additional features.

### Kearns-Sayre Syndrome (KSS)

KSS is caused by large-scale mtDNA deletions, usually single sporadic deletions of 1.1-10 kb. Onset occurs before age 20. The clinical triad consists of progressive external ophthalmoplegia (PEO), pigmentary retinopathy, and one of the following: cardiac conduction block, CSF protein greater than 100 mg/dL, or cerebellar ataxia. Cardiac surveillance is mandatory because of the risk of sudden cardiac death from heart block, and pacemaker placement may be lifesaving.

### Leber Hereditary Optic Neuropathy (LHON)

Three common mtDNA point mutations account for most cases: m.11778G>A (most common), m.3460G>A, and m.14484T>C. Young adult males are predominantly affected due to incomplete penetrance, especially in females. The presentation is acute or subacute bilateral sequential painless visual loss progressing over weeks to months. Fundoscopy shows peripapillary telangiectasia and pseudoedema of the optic disc early, with optic atrophy developing later. Idebenone, a synthetic CoQ10 analog approved in Europe, may improve visual outcomes if started early. Gene therapy (lenadogene nolparvovec) has been approved in the EU for the m.11778G>A mutation.

### POLG-Related Disorders

POLG encodes the catalytic subunit of mitochondrial DNA polymerase gamma. Inheritance is autosomal recessive in most cases, though autosomal dominant forms exist. The phenotypic spectrum includes Alpers syndrome (childhood-onset hepatocerebral degeneration with refractory seizures and liver failure), mitochondrial recessive ataxia syndrome (MIRAS/SANDO, featuring ataxia, neuropathy, and ophthalmoplegia), and progressive external ophthalmoplegia with secondary mtDNA deletions. Valproic acid is strictly contraindicated in POLG mutations because it can trigger fatal hepatotoxicity. POLG sequencing should be considered before starting valproic acid in any patient with unexplained epilepsy and features suggestive of mitochondrial disease.

![MRI showing stroke-like lesions in MELAS not conforming to vascular territories](images/melas-mri.jpg)

## Diagnosis

### Laboratory Studies

Serum lactate may be elevated, and the lactate-to-pyruvate ratio (greater than 20 suggests mitochondrial dysfunction) is informative. CSF lactate is more reliable than serum and is elevated in MELAS and other mitochondrial encephalopathies. Creatine kinase may be mildly elevated. Serum FGF-21 and GDF-15 are emerging biomarkers for mitochondrial myopathy.

### Genetic Testing

Blood mtDNA testing can detect common point mutations (m.3243A>G, m.8344A>G, LHON mutations). However, heteroplasmy levels in blood may decrease with age, so urine epithelial cells and muscle tissue may show higher mutant loads and should be tested when clinical suspicion is high and blood testing is negative. mtDNA deletion analysis using Southern blot or long-range PCR is performed for suspected KSS or PEO. Nuclear gene panels or WES are used for suspected nuclear-encoded mitochondrial disease involving genes such as POLG, TWNK, and SURF1. Muscle biopsy with respiratory chain enzyme analysis remains important when genetic testing is inconclusive.

### Muscle Biopsy

Modified Gomori trichrome staining reveals ragged red fibers. SDH staining shows "ragged blue fibers" with subsarcolemmal SDH accumulation. COX staining demonstrates COX-negative fibers reflecting cytochrome c oxidase deficiency. Respiratory chain enzyme activity assays quantify individual complex deficiencies.

![Muscle biopsy histopathology showing ragged red fibers and COX-negative fibers in mitochondrial myopathy](images/mitochondrial-muscle-biopsy.jpg)

## Management

No curative treatment exists for most mitochondrial diseases. Supportive care includes CoQ10 supplementation (evidence is limited but it is widely used), L-carnitine, B vitamins, and exercise training (endurance exercise may improve mitochondrial biogenesis). Metabolic stressors such as prolonged fasting, extreme temperatures, and physiological stress should be avoided. Mitochondrial toxins must also be avoided, including valproic acid (especially in POLG), aminoglycosides (in m.1555A>G carriers), statins (used with caution), and tetracyclines. Annual cardiac surveillance with ECG and echocardiography is essential, especially in KSS. For seizure management, levetiracetam, lacosamide, and lamotrigine are generally safer, while valproic acid should be avoided. Genetic counseling is complex due to heteroplasmy and variable penetrance; preimplantation genetic testing and mitochondrial replacement therapy (available in some jurisdictions) are options for mtDNA mutations.

## Clinical Pearls

Mitochondrial disease should be considered in any patient with unexplained multisystem disease, especially when the nervous system, muscle, heart, and endocrine organs are involved. Valproic acid is contraindicated in POLG-related disorders and can trigger fatal hepatotoxicity; POLG testing should be considered before starting valproate in patients with epilepsy and features of mitochondrial disease. Stroke-like episodes in a young person that do not respect vascular territories, especially with lactic acidosis and hearing loss, should raise suspicion for MELAS. Blood mtDNA heteroplasmy levels can decrease with age, so if clinical suspicion is high and blood testing is negative, urine or muscle tissue should be tested for higher sensitivity. Cardiac conduction defects in Kearns-Sayre syndrome can be fatal, and annual cardiac monitoring with proactive pacemaker placement saves lives.

## References

1. Gorman GS, Chinnery PF, DiMauro S, et al. Mitochondrial diseases. *Nat Rev Dis Primers*. 2016;2:16080.
2. Ng YS, Turnbull DM. Mitochondrial disease: genetics and management. *J Neurol*. 2016;263(1):179-191.
3. Rahman J, Rahman S. Mitochondrial medicine in the omics era. *Lancet*. 2018;391(10139):2560-2574.
4. El-Hattab AW, Adesina AM, Jones J, Scaglia F. MELAS syndrome: clinical manifestations, pathogenesis, and treatment options. *Mol Genet Metab*. 2015;116(1-2):4-12.